Targeting GLUT1 to develop anti-tumor drugs or diagnostic reagents, blocking the source of nutrients for cells, or disguising drugs as nutrients and supplying them to tumor cells in large quantities has become a focus for the development of anti-tumor reagents. Here, SLC2A1 is linked to neoplasm.